|  | Local recurrence | Recurrence-free survival | ||||
---|---|---|---|---|---|---|---|
Variable | Â | Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value |
Nottigham grade | 2 vs. 3 | 0.30 | 0.05–1.81 | 0.43 | 0.67 | 0.24–1.88 | 0.75 |
Menopausal status | Post vs. pre | 0.25 | 0.03–2.10 | 0.44 | 1.32 | 0.57–3.06 | 0.81 |
LVI | No vs. Yes | 0.69 | 0.15–3.08 | 0.63 | 0.48 | 0.19–1.22 | 0.12 |
Pathological nodal status | No vs. yes | 1.33 | 0.16–11.03 | 0.79 | 0.41 | 0.05–3.05 | 0.38 |
Tumour size before surgery |  | 1.09 | 0.86–1.38 | 0.47 | 1.24 | 1.08–1.42 | 0.003 |
Tumour size at surgery |  | 1.03 | 0.85–1.24 | 0.77 | 1.18 | 1.09–1.29 | < 0.001 |
Miller-Payne score |  | 0.74 | 0.42–1.32 | 0.31 | 0.56 | 0.4–0.8 | 0.001 |
Chevallier score |  | 0.96 | 0.46–2.02 | 0.92 | 2.01 | 1.14–3.53 | 0.015 |
Standard pathology response | Â | Â | Â | 0.51 | Â | Â | 0.05 |
 | NR vs. pCR | 3.98 | 0.36–44.0 |  | 13.29 | 1.6–110.5 |  |
 | PR vs. pCR | 2.07 | 0.24–17.7 |  | 7.43 | 0.99–56.1 |  |
Pretreatment stage group | Â | Â | Â | 0.51 | Â | Â | 0.05 |
 | II vs. III | 0.62 | 0.15–2.61 |  | 0.41 | 0.17–1.0 |  |